# Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

> **NCT00242528** · PHASE4 · WITHDRAWN · sponsor: **Novartis**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00242528
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242528, "Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00242528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*